Sponsors

Exhibitors

Precision Medicine Conference 2016
Seven Bridges
ICON Symbol of Excellence
Omicia
Linguamatics

precision medicine forum conference London 2016

AGENDA


8.00        Registration

9.10        Opening Remarks from The Chair:

Vivienne Parry OBE                           

9.15        Keynote Panel Session

George Freeman MP, UK Minister for Life Sciences, Dept. of Health

Sir John Chisholm, Executive Chair, Genomics England

Prof. Sue Hill, Chief Scientific Officer, NHS England

10.15     Recent Success Stories and The Future of Cancer

Dr Rowena Sharpe, Head of Precision Medicine, Cancer Research UK

Dr Clare Turnbull, Clinical Lead for 100K Genome Project Cancer Programme, Genomics England

11.15     Refreshments and Networking

11.45     Integrating Personal Genomics, Big Data and Bioinformatics

The Challenges of a large scale genome project:

Dr Damian Smedley will give examples of some of the hurdles to overcome in the course of the 100K Genome project and lessons learned

Dr Damian Smedley, Director of Genomic Interpretation and Associate Director of Bioinformatics, Genomics England

From biobanks and big data to precision cancer medicine:

Caroline Heckman PhD’s research is focused on understanding basic mechanisms of cancer pathogenesis and drug resistance using big data platforms such as high throughput screening and next generation genome sequencing, with results applied real time for patient care. The findings are also used to identify new treatment strategies, particularly for patients with recurrent disease, identify biomarkers for treatment response, and develop new methods for patient stratification.

Caroline Heckman PhD, Group Leader and Principal Investigator, Institute for Molecular Medicine Finland (FIMM)

Bioinformatics Goes Translational: Infrastructural Challenges and Opportunities:

Molecular biology is increasingly relevant to clinical research and, in some cases, practicing medicine. This is because the costs of automated data-gathering technologies – most notably DNA sequencing but also proteomics and metabolomics – have dropped precipitously over the past decade and continue to fall. Coupled with cost–effective imaging techniques, a large amount of data can be gathered and integrated to help inform both clinical research and practicing medicine.

Rolf Apweiler, Director, EMBL-EBI (European Bioinformatics Institute)

Julia Fan Li, Senior Vice President, Seven Bridges

12.45    Tom O’Leary, Chief Information Officer, ICON Plc

13.00    The Global View of Precision Medicine from the perspective of big pharama:

Dr Menelas N Pangalos FMedSci, Executive Vice President, AstraZeneca’s Innovative Medicines and Early Development Biotech Unit

13.30     Networking Lunch

14.30     Round-table sessions:

Following extensive research and consultation with the key industry stakeholders we drill down to uncover what the major issues facing us in the implementation of Precision Medicine are. These issues form the basis of the round-table sessions.  After an introduction by the moderator and brief introduction from each participant as to their role and responsibility, the session then continues with all participants fully engaged in the sharing of ideas, experiences, business process and opinion. The sessions will have 10-12 topics from which attendees can choose their preference.

Each moderator will present the main themes of the round table they chaired allowing the whole audience to get a feel for some of the key issues discussed around each topic

Choose from one of the following:

  • Health Economics
  • Rare Disease
  • Oncology
  • Next Generation Sequencing
  • CTC’s/Liquid Biopsy
  • Building global, multi-discipline partnerships
  • Clinical implementation of Precision Medicine
  • Pharmacogenomics
  • Big data and analytics
  • Companion Diagnostics
  • Biomarker
  • Clinical Trials
  • Proteomics

16.00     Refreshments and Networking

16.30     Building a Patient Cohort – Experiences of The Precision Medicine Initiative in the U.S.A.

Dr Mark A. Rubin, Founding Director, Englander Institute for Precision Medicine, Weill Cornell Medical College and New York-Presbyterian Hospital

17.00     The Patients perspective

Hear from a panel of patients about their experiences of precision medicine. This session really brings the concept of precision medicine into reality.

Some of the areas covered will include:

  • Data ownership
  • How many biopsies are too many biopsies
  • Public perception of Precision Medicine
  • Dynamic consent

18.00     Networking Drinks reception

9.00        Opening remarks

9.05        Rare Disease and Patient Access:

The role of patients and families in shaping research – and the opportunities/potential for improving the design of clinical development programmes so they get to the point where they can both satisfy the Regulators of their quality, safety and efficacy and the HTA bodies of their clinical and cost effectiveness more quickly and effectively

Alastair Kent OBE, Director, Genetic Alliance UK

  • The UK compared to EU related to adoption of EMA approved orphan medicines
  • The historical framework for HTA assessment of orphan medicines in the UK
  • How does NICE HST and the Office for Market Access interact with industry
  • Case study of BioMarin and managed entry through NICE HST
  • Lessons learned and future trends.

Nigel Nicholls, Director and Country Manager UK/Ireland, BioMarin Europe Ltd

Sheela Upadhyaya, Associate Director – Highly Specialised Technologies, NICE

Edmund Jessop, Public Health Adviser

10.15     The Economics of Precision Medicine:

Rethinking Healthcare – The Need for a New System

The use of biomarkers in personalized medicine bears the potential to discover, develop and market new treatments that may significantly increase therapy effectiveness for serious diseases such as cancer or disorders of the central nervous system. However, if treatments are ‘personalised’, the targeted patient population shrinks. As a result, personalised treatments are introduced at premium prices in order to still create a profit for the developer or marketer. Extrapolating healthcare expenses by considering expected launches of new, biomarker-enabled personalised therapies shows that either healthcare budgets will need to grow substantially, or that costs of clinical development and marketing have to go down significantly in order to create sustainable healthcare systems.

The contribution will discuss the following issues:

  • premium product pricing and value to patients and drug developers
  • future healthcare budget requirements
  • potential approaches to make healthcare systems sustainable.

Joachim M. Greuel, Ph.D., MBA, Managing Director, Bioscience Valuation BSV GmbH

Prof Katherine Payne, Professor of Health Economics The University of Manchester

11.15     Refreshments and Networking

11.45     The Critical Role of Biomarkers & Companion Diagnostics Development:

Global Commercialization and Market Access for Companion Diagnostics

Iain D. Miller, Ph.D. Founder, Healthcare Strategies Group

Liquid Biopsy

The concept of liquid biopsy may provide an important milestone towards precision medicine in cancer therapy by enabling longitudinal treatment monitoring and providing actionable information for therapy selection. Circulating Tumour Cells (CTCs), circulating free tumour DNA (ctDNA) and circulating micro-RNAs (miRNAs) as blood-based biomarkers offer the possibility to detect driver mutations, emerging resistance and epigenetic changes in molecular pathomechanisms. However, the currently available technologies for enrichment, isolation and analysis of the markers lack harmonised protocols for pre-analytical sample handling and biobanking, analytical standards and defined workflows for downstream analysis. The Innovative Medicines Initiative consortium CANCER-ID addresses the issues in a public-private partnership reaching out to all relevant stakeholders.

Dr. Thomas Schlange, Senior Biomarker Scientist, Bayer and EFPIA coordinator Innovative Medicines Initiative (IMI) consortium CANCER-ID

Yiu-Lian Fong, Ph.D, MBA, Senior Director, Global Diagnostic Innovation, Johnson & Johnson

13.00     Networking Lunch

14.00     At the cutting edge of Biomedical discovery

Dr David Roblin FRCP FFPM, Chief Operating Officer & Director of Scientific Translation, The Francis Crick Institute

14.30     Implementing Precision Medicine in the Clinic:

Prof. Dr. med. Nissan Peter Malek, Director Center for Personalised Medicine, University of Tübingen Managing Director Dept. of Internal Medicine, University Hospital Tübingen

Dr Mark A. Rubin, Founding Director, Englander Institute for Precision Medicine, Weill Cornell Medical College and New York Presbyterian Hospital

Mainstreaming genomics in the health system

Based on long experience of working with different clinical specialties to develop national guidance and policy to support the widespread use of effective genomic tools, the PHG Foundation is leading an ongoing initiative in partnership with the Royal College of Physicians and Health Education England to boost clinical engagement with genomics as an essential prerequisite to widespread personalised medicine within the NHS. This includes dedicated educational resources and a leadership group of ‘clinical champions’. There are over 200,000 clinicians in the UK, very few of whom are either clinical geneticists or likely to undertake the HEE Masters in Genomic Medicine – but all of whom should be aware of emerging opportunities to improve patient care in their own specialties.

Dr Hilary Burton, Director, PHG Foundation

15.15     Omics – the big debate:

There is much debate about the interplay between genomics, proteomics, pharmacogenomics and other ‘omics. Discover which takes the lead and how they can be used in tandem in the quest for improved patient outcomes. The development and application of proteomics and mass spectrometry to clinical biomarker research for precision medicine.

Professor Tony Whetton, Director of the Stoller Centre for Biomarker Discovery and also the Manchester Precision Medicine Institute. Principal investigator of the Leukaemia Lymphoma Research Mass Spectrometry programme based at the Wolfson Molecular Imaging Centre, Christie Hospital

16.15     Partnerships in Precision Medicine – The crucial need for collaboration

Dr Ruth McKernan, Chief Executive, Innovate UK

17.15     Closing Remarks from The Chair

Vivienne Parry OBE

17.20     Conference Close

Precision Medicine Forum London 2016


Download Programme – Precision Medicine Forum London 2016
Vivienne Parry OBE (Chair Precision Medicine Forum Conference London 2016

Vivienne Parry OBE (Chair)

A scientist by training, Vivienne hosts medical programmes for Radio 4, writes widely on health, presents films, facilitates many high level conferences and debates and trains young researchers. She also has a part time role as head of engagement at Genomics England which is delivering the 100,000 Genomes Project.

Vivienne will be chairing the London 2016 Conference.

Share This